← Back to Search

Cannabinoid

Pure Green Sublingual Tablet - Daily for Pain

Phase 2
Waitlist Available
Led By Debra Kimless, M.D.
Research Sponsored by Pure Green
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30 days
Awards & highlights

Summary

This trial is testing Pure Green sublingual tablets to see if they are safe and effective for reducing knee pain in people with osteoarthritis. The tablets dissolve under the tongue to quickly deliver pain-relieving ingredients.

Eligible Conditions
  • Pain
  • Osteoarthritis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 30 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Impact of Pure Green sublingual tablets on pain due to osteoarthritis of the knee using a daily self-reported pain scale score.
Secondary study objectives
Impact of Pure Green sublingual tablets on anxiety of patients with osteoarthritis if the knee
Impact of Pure Green sublingual tablets on general health and well-being of Osteoarthritis of the knee patients.
Impact of Pure Green sublingual tablets on sleep improvement of patients with osteoarthritis of the knee.
+1 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Pure Green Sublingual Tablet - DailyExperimental Treatment1 Intervention
Subjects will take 2 tablets daily, one in the morning and one in the evening, and are able to take up to 2 additional tablets per day as needed for pain.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Test Article
2019
N/A
~110

Find a Location

Who is running the clinical trial?

Pure GreenLead Sponsor
5 Previous Clinical Trials
194 Total Patients Enrolled
Debra Kimless, M.D.Principal InvestigatorChief Medical Officer
4 Previous Clinical Trials
178 Total Patients Enrolled
~6 spots leftby Oct 2025